SG145773A1 - Therapeutic treatment - Google Patents

Therapeutic treatment

Info

Publication number: SG145773A1
Authority: SG; Singapore
Prior art keywords: therapeutic treatment; prevention; treatment; candesartan; rosuvastatin
Prior art date: 2003-09-26

Application number

SG200806320-8A

Other languages

English (en)

Inventor

Jay Lal Mehta

Original Assignee

Astrazeneca Uk Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-09-26

Filing date

2004-09-22

Publication date

2008-09-29

2004-09-22 Application filed by Astrazeneca Uk Ltd filed Critical Astrazeneca Uk Ltd

2008-09-29 Publication of SG145773A1 publication Critical patent/SG145773A1/en

Links

230000001225 therapeutic effect Effects 0.000 title 1
230000002265 prevention Effects 0.000 abstract 2
206010003210 Arteriosclerosis Diseases 0.000 abstract 1
239000002053 C09CA06 - Candesartan Substances 0.000 abstract 1
208000011775 arteriosclerosis disease Diseases 0.000 abstract 1
SGZAIDDFHDDFJU-UHFFFAOYSA-N candesartan Chemical compound CCOC1=NC2=CC=CC(C(O)=O)=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SGZAIDDFHDDFJU-UHFFFAOYSA-N 0.000 abstract 1
229960000932 candesartan Drugs 0.000 abstract 1
230000007211 cardiovascular event Effects 0.000 abstract 1
BPRHUIZQVSMCRT-VEUZHWNKSA-N rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 abstract 1
229960000672 rosuvastatin Drugs 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Rheumatology (AREA)
Vascular Medicine (AREA)
Pain & Pain Management (AREA)
Urology & Nephrology (AREA)
Hospice & Palliative Care (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Plural Heterocyclic Compounds (AREA)
Medical Preparation Storing Or Oral Administration Devices (AREA)
Materials For Medical Uses (AREA)

SG200806320-8A 2003-09-26 2004-09-22 Therapeutic treatment SG145773A1 (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GBGB0322552.1A GB0322552D0 (en)	2003-09-26	2003-09-26	Therapeutic treatment

Publications (1)

Publication Number	Publication Date
SG145773A1 true SG145773A1 (en)	2008-09-29

Family

ID=29286881

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SG200806320-8A SG145773A1 (en)	2003-09-26	2004-09-22	Therapeutic treatment

Country Status (28)

Country	Link
US (2)	US7932263B2 (de)
EP (1)	EP1673091B1 (de)
JP (1)	JP4841433B2 (de)
KR (1)	KR101129767B1 (de)
CN (1)	CN100515421C (de)
AT (1)	ATE451103T1 (de)
AU (1)	AU2004275567B2 (de)
BR (1)	BRPI0414724A (de)
CA (1)	CA2540102C (de)
CY (1)	CY1109814T1 (de)
DE (1)	DE602004024555D1 (de)
DK (1)	DK1673091T3 (de)
ES (1)	ES2336450T3 (de)
GB (1)	GB0322552D0 (de)
HR (1)	HRP20100080T1 (de)
IL (1)	IL174536A (de)
IS (1)	IS2729B (de)
MX (1)	MXPA06003353A (de)
NO (1)	NO335813B1 (de)
NZ (1)	NZ546162A (de)
PL (1)	PL1673091T3 (de)
PT (1)	PT1673091E (de)
RU (1)	RU2358737C2 (de)
SG (1)	SG145773A1 (de)
SI (1)	SI1673091T1 (de)
UA (1)	UA90249C2 (de)
WO (1)	WO2005030215A2 (de)
ZA (1)	ZA200602433B (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB0001662D0 (en) *	1999-02-06	2000-03-15	Zeneca Ltd	Pharmaceutical compositions
GB0003305D0 (en)	2000-02-15	2000-04-05	Zeneca Ltd	Pyrimidine derivatives
GB0218781D0 (en)	2002-08-13	2002-09-18	Astrazeneca Ab	Chemical process
GB0312896D0 (en)	2003-06-05	2003-07-09	Astrazeneca Ab	Chemical process
GB0322552D0 (en)	2003-09-26	2003-10-29	Astrazeneca Uk Ltd	Therapeutic treatment
GB0324791D0 (en)	2003-10-24	2003-11-26	Astrazeneca Ab	Chemical process
WO2007051007A2 (en) *	2005-10-28	2007-05-03	Novartis Ag	Combination of antihypertensives with cholesterol-lowering agent
BR112012006939A2 (pt) *	2009-09-29	2015-09-08	Butamax Tm Advanced Biofuels	célula hospedeira de produção de levedura recombinante e método para a produção de um produto selecionado do grupo que consiste em 2,3-butanodiol, isobutanol, 2-butanol, 1-butanol, 2-butanona, valina, leucina, ácido lático, ácido málico, álcool, isoampilico e isoprenoides
US20120239131A1 (en) *	2011-03-15	2012-09-20	Medtronic Vascular, Inc.	Methods and apparatus for treatment of aneurysmal tissue
WO2013083286A1 (en) *	2011-12-09	2013-06-13	Farmicom Pharmaceutical Company D.O.O.	TREATMENT OF ARTERIAL WALL BY COMBINATION OF RAAS INHIBITOR AND HMG-CoA REDUCTASE INHIBITOR
CN103479627A (zh) *	2013-05-16	2014-01-01	武汉光谷百桥国际生物科技有限公司	一种血管紧张素ii的i型受体拮抗剂在促进毛发生长方面的应用
KR101771766B1 (ko)	2013-12-30	2017-08-28	알보젠코리아 주식회사	안지오텐신-Ⅱ 수용체 차단제 및 HMG-CoA 환원효소 저해제를 포함하는 약제학적 복합제제
UA122847C2 (uk) *	2016-11-15	2021-01-06	Елджі Кем, Лтд.	Лікувальний комплекс для лікування діабету другого типу та діабетичної дисліпідемії

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5196444A (en) *	1990-04-27	1993-03-23	Takeda Chemical Industries, Ltd.	1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof
US6004989A (en) *	1990-04-27	1999-12-21	Takeda Chemical Industries, Ltd.	Benzimidazole derivatives, their production and use
US5703110A (en) *	1990-04-27	1997-12-30	Takeda Chemical Industries, Ltd.	Benzimidazole derivatives, their production and use
US5298497A (en) *	1990-05-15	1994-03-29	E. R. Squibb & Sons, Inc.	Method for preventing onset of hypertension employing a cholesterol lowering drug
CA2040865C (en)	1990-05-15	2002-07-23	James L. Bergey	Method for preventing, stabilizing or causing regression of atherosclerosis employing a combination of a cholesterol lowering drug and an ace inhibitor
JP2648897B2 (ja)	1991-07-01	1997-09-03	塩野義製薬株式会社	ピリミジン誘導体
WO1993008823A1 (en)	1991-11-06	1993-05-13	Tanabe Seiyaku Co., Ltd.	Guanidinyl and related cell adhesion modulation compounds
CA2125251C (en)	1993-06-07	2005-04-26	Yoshiyuki Inada	A pharmaceutical composition for angiotensin ii-mediated diseases
US5721263A (en) *	1993-06-07	1998-02-24	Takeda Chemical Industries, Ltd.	Pharmaceutical composition for angiotensin II-mediated diseases
CA2186606A1 (en) *	1994-03-29	1995-10-05	Edward B. Nelson	Treatment of atherosclerosis with angiotensin ii receptor blocking imidazoles
FR2741620B1 (fr)	1995-11-28	1997-12-26	Oreal	Procede de preparation de composes a groupement beta-hydroxy -delta-lactone analogues de la (+) compactine et de la (+) mevinoline
PL189066B1 (pl)	1996-04-05	2005-06-30	Takeda Pharmaceutical	Kompozycja farmaceutyczna do zapobiegania lub zwalczania chorób związanych z angiotensyną II oraz stosowanie związków do wytwarzania leku do zapobiegania lub zwalczania chorób związanych z angiotensyną II
DE69734405T2 (de) *	1996-07-15	2006-08-03	Sankyo Co., Ltd.	Verwendung von CS-866 (Olmersartan) zur Herstellung eines Medikaments für die Behandlung von Arteriosklerose
JPH1081633A (ja)	1996-07-16	1998-03-31	Sankyo Co Ltd	医薬組成物
GT199800126A (es)	1997-08-29	2000-01-29		Terapia de combinacion.
HN1998000124A (es)	1997-08-29	1999-02-09	Pfizer Prod Inc	Terapia de combinacion
GB9900339D0 (en)	1999-01-09	1999-02-24	Zeneca Ltd	Chemical compounds
AR022462A1 (es)	1999-02-06	2002-09-04	Astrazeneca Uk Ltd	Uso de un agente que disminuye el colesterol
GB0000710D0 (en)	1999-02-06	2000-03-08	Zeneca Ltd	Drug combination
GB0001662D0 (en) *	1999-02-06	2000-03-15	Zeneca Ltd	Pharmaceutical compositions
GB9903472D0 (en)	1999-02-17	1999-04-07	Zeneca Ltd	Chemical process
US6294192B1 (en)	1999-02-26	2001-09-25	Lipocine, Inc.	Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US6248363B1 (en)	1999-11-23	2001-06-19	Lipocine, Inc.	Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
TR200102944T2 (tr)	1999-04-13	2002-08-21	Basf Aktiengesellschaft	İntegrin reseptör ligandları
PL353199A1 (en)	1999-08-30	2003-11-03	Aventis Pharma Deutschland Gmbh	Use of inhibitors of the renin-angiotensin system in the prevention of cardiovascular events
AU782386C (en)	1999-08-31	2006-08-10	Brigham And Women's Hospital	Systemic inflammatory markers as diagnostic tools in the prevention of atherosclerotic diseases
PH12000002657B1 (en)	1999-10-12	2006-02-21	Bristol Myers Squibb Co	C-aryl glucoside SGLT2 inhibitors
US6720001B2 (en)	1999-10-18	2004-04-13	Lipocine, Inc.	Emulsion compositions for polyfunctional active ingredients
GB0001621D0 (en)	2000-01-26	2000-03-15	Astrazeneca Ab	Pharmaceutical compositions
GB0003305D0 (en)	2000-02-15	2000-04-05	Zeneca Ltd	Pyrimidine derivatives
WO2001072706A1 (en)	2000-03-28	2001-10-04	Biocon India Limited	Synthesis of [r-(r,r)]-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid hemi calcium salt (atorvastatin)
AR030414A1 (es)	2000-04-03	2003-08-20	Astrazeneca Ab	Combinacion farmaceutica que comprende un beta bloqueante y un inhibidor de hmg-coa reductasa , formulacion farmaceutica, equipo transportable de partes , uso de esta combinacion y de esta formulacion para preparar medicamentos
GB2361185A (en)	2000-04-10	2001-10-17	Nicholas J Wald	Pharmaceutical formulation for the prevention of cardiovascular disease
RU2298418C2 (ru) *	2000-04-12	2007-05-10	Новартис Аг	Комбинация по меньшей мере двух соединений, выбранных из групп антагонистов at1-рецептора или ингибиторов асе (ангиотензинпревращающий фермент), или ингибиторов hmg-coa-редуктазы (бета-гидрокси-бета-метилглутарил-кофермент-а-редуктаза)
US6620821B2 (en) *	2000-06-15	2003-09-16	Bristol-Myers Squibb Company	HMG-CoA reductase inhibitors and method
WO2002017913A1 (en) *	2000-08-30	2002-03-07	Sankyo Company, Limited	Medicinal compositions for preventing or treating heart failure
JP2002145770A (ja) *	2000-08-30	2002-05-22	Sankyo Co Ltd	心不全の予防又は治療のための医薬組成物
GB0028429D0 (en)	2000-11-22	2001-01-10	Astrazeneca Ab	Therapy
PT1385548E (pt) *	2001-01-26	2007-08-24	Schering Corp	Combinações de um inibidor ou de inibidores de absorção de esteróis com agente (s) para o tratamento de doenças vasculares
AR035533A1 (es) *	2001-01-26	2004-06-02	Schering Corp	Uso de por lo menos un inhibidor de la absorcion de los esteroles o sus sales, solvatos, prodrogas farmaceuticamente aceptables o mezclas de los mismos para la preparacion de un medicamento para el tratamiento de la sitosterolemia, composiciones farmaceuticas, el uso de dichas composiciones para la
WO2002095402A2 (en) *	2001-04-18	2002-11-28	Mcgill University	Individualization of therapy with hyperlipidemia agents
SE0103509D0 (sv)	2001-10-19	2001-10-19	Astrazeneca Ab	Rosuvastatin in pre demented states
EA008596B1 (ru)	2003-04-29	2007-06-29	Пфайзер Инк.	5,7-ДИАМИНОПИРАЗОЛО[4,3-d]ПИРИМИДИНЫ, ПОЛЕЗНЫЕ ПРИ ЛЕЧЕНИИ ГИПЕРТЕНЗИИ
GB0312896D0 (en)	2003-06-05	2003-07-09	Astrazeneca Ab	Chemical process
UY28501A1 (es)	2003-09-10	2005-04-29	Astrazeneca Uk Ltd	Compuestos químicos
GB0321827D0 (en)	2003-09-18	2003-10-15	Astrazeneca Uk Ltd	Chemical compounds
GB0322552D0 (en)	2003-09-26	2003-10-29	Astrazeneca Uk Ltd	Therapeutic treatment
JP2005126338A (ja)	2003-10-21	2005-05-19	Boehringer Ingelheim Pharma Gmbh & Co Kg	心不全治療剤
GB0324791D0 (en)	2003-10-24	2003-11-26	Astrazeneca Ab	Chemical process
US20060078615A1 (en)	2004-10-12	2006-04-13	Boehringer Ingelheim International Gmbh	Bilayer tablet of telmisartan and simvastatin

2003
- 2003-09-26 GB GBGB0322552.1A patent/GB0322552D0/en not_active Ceased
2004
- 2004-09-22 JP JP2006527488A patent/JP4841433B2/ja not_active Expired - Lifetime
- 2004-09-22 SI SI200431337T patent/SI1673091T1/sl unknown
- 2004-09-22 RU RU2006113366/15A patent/RU2358737C2/ru not_active IP Right Cessation
- 2004-09-22 DE DE602004024555T patent/DE602004024555D1/de not_active Expired - Lifetime
- 2004-09-22 PT PT04768663T patent/PT1673091E/pt unknown
- 2004-09-22 MX MXPA06003353A patent/MXPA06003353A/es active IP Right Grant
- 2004-09-22 SG SG200806320-8A patent/SG145773A1/en unknown
- 2004-09-22 PL PL04768663T patent/PL1673091T3/pl unknown
- 2004-09-22 WO PCT/GB2004/004120 patent/WO2005030215A2/en not_active Ceased
- 2004-09-22 US US10/573,353 patent/US7932263B2/en active Active
- 2004-09-22 AT AT04768663T patent/ATE451103T1/de active
- 2004-09-22 NZ NZ546162A patent/NZ546162A/en not_active IP Right Cessation
- 2004-09-22 ES ES04768663T patent/ES2336450T3/es not_active Expired - Lifetime
- 2004-09-22 HR HR20100080T patent/HRP20100080T1/hr unknown
- 2004-09-22 CN CNB2004800348230A patent/CN100515421C/zh not_active Expired - Lifetime
- 2004-09-22 EP EP04768663A patent/EP1673091B1/de not_active Expired - Lifetime
- 2004-09-22 BR BRPI0414724-3A patent/BRPI0414724A/pt active Search and Examination
- 2004-09-22 KR KR1020067007973A patent/KR101129767B1/ko not_active Expired - Fee Related
- 2004-09-22 CA CA2540102A patent/CA2540102C/en not_active Expired - Fee Related
- 2004-09-22 UA UAA200603434A patent/UA90249C2/uk unknown
- 2004-09-22 AU AU2004275567A patent/AU2004275567B2/en not_active Ceased
- 2004-09-22 DK DK04768663.9T patent/DK1673091T3/da active
2006
- 2006-03-23 IL IL174536A patent/IL174536A/en unknown
- 2006-03-24 ZA ZA200602433A patent/ZA200602433B/en unknown
- 2006-04-20 NO NO20061744A patent/NO335813B1/no not_active IP Right Cessation
- 2006-04-21 IS IS8421A patent/IS2729B/is unknown
2010
- 2010-02-16 CY CY20101100154T patent/CY1109814T1/el unknown
- 2010-06-11 US US12/813,917 patent/US20110046119A1/en not_active Abandoned

Also Published As

Publication number	Publication date
AU2004275567B2 (en)	2008-01-10
IS8421A (is)	2006-04-21
DE602004024555D1 (de)	2010-01-21
DK1673091T3 (da)	2010-03-22
HK1090553A1 (en)	2006-12-29
JP4841433B2 (ja)	2011-12-21
IL174536A (en)	2010-12-30
US7932263B2 (en)	2011-04-26
PT1673091E (pt)	2010-02-15
AU2004275567A1 (en)	2005-04-07
ZA200602433B (en)	2007-06-27
NO20061744L (no)	2006-06-22
IS2729B (is)	2011-04-15
US20110046119A1 (en)	2011-02-24
IL174536A0 (en)	2008-04-13
CA2540102A1 (en)	2005-04-07
RU2358737C2 (ru)	2009-06-20
ES2336450T3 (es)	2010-04-13
CY1109814T1 (el)	2014-09-10
EP1673091B1 (de)	2009-12-09
RU2006113366A (ru)	2007-11-10
KR101129767B1 (ko)	2012-03-26
EP1673091A2 (de)	2006-06-28
MXPA06003353A (es)	2006-06-08
BRPI0414724A (pt)	2006-11-21
SI1673091T1 (sl)	2010-03-31
ATE451103T1 (de)	2009-12-15
WO2005030215A3 (en)	2005-06-02
CN100515421C (zh)	2009-07-22
CA2540102C (en)	2012-07-24
JP2007506720A (ja)	2007-03-22
NO335813B1 (no)	2015-02-23
UA90249C2 (uk)	2010-04-26
PL1673091T3 (pl)	2010-04-30
CN1886136A (zh)	2006-12-27
GB0322552D0 (en)	2003-10-29
WO2005030215A2 (en)	2005-04-07
KR20060108623A (ko)	2006-10-18
HRP20100080T1 (hr)	2010-04-30
NZ546162A (en)	2008-11-28
US20070275989A1 (en)	2007-11-29

Publication	Publication Date	Title
CY1109814T1 (el)	2014-09-10	Ενας συνδυασμος που περιεχει candesartan και rosuvastatin για τη θεραπευτικη αντιμετωπιση της αρτηριοσκληρυνσης
AU2004208615B2 (en)	2007-05-03	Medicine for prevention of and treatment for arteriosclerosis and hypertension
SI1487541T1 (sl)	2009-02-28	Uporaba inhibitorjev il-18 za zdravljenje in /alipreventivo bolezni perifernega oĺ˝ilja
TW200626526A (en)	2006-08-01	Pharmaceutical compositions for the treatment of neoplasms
PL374846A1 (en)	2005-11-14	New compounds for the inhibition of rotamases and use thereof
GB0223040D0 (en)	2002-11-13	Therapeutic compounds
AU2003290548A1 (en)	2004-06-07	Prevention and treatment of synucleinopathic disease
EP1551393A4 (de)	2010-06-16	Kombinationstherapie gegen depression, prävention von suizid und verschiedener medizinischer und psychiatrischer erkrankungen
YU82602A (sh)	2006-01-16	Korišćenje il-18 inhibitora za lečenje i/ili prevenciju ateroskleroze
AU2003251875A1 (en)	2004-02-02	Combination therapy for the treatment of neoplasms
MXPA03006776A (es)	2003-10-24	Uso de inhibidores de interleucina-18 para el tratamiento y/o prevencion de enfermedad cardiaca.
IL162818A0 (en)	2005-11-20	Combination therapy for the treatment of bacterialinfections
TW200503707A (en)	2005-02-01	Application of intestinal biliary acid reuptake inhibitors for the prevention and threatment of alzheimer's disease
AU2003213898A1 (en)	2003-10-13	Prevention and treatment of mycoplasma-associated diseases
AU2003231279A8 (en)	2003-11-17	Prevention and treatment of type 2 diabetes
PL373000A1 (en)	2005-08-08	Combination of a proton pump inhibitor and a respiratory agent for the treatment of respiratory diseases
AU2003239494A1 (en)	2003-12-02	Methods using a combination of a 3-heteroaryl-2-indolinone and a cyclooxygenase-2 inhibitor for the treatment of neoplasia
AU2003239284A1 (en)	2003-12-31	Combination of pde-v inhibitors and nk1 antagonists for the treatment of depression
AU2003208288A1 (en)	2003-09-02	Deuterated biphenyl-substituted benzimidazoles and medicament containing said compounds for the treatment of hypertonia
AU2003304316A8 (en)	2005-01-28	Compounds and methods for the treatment and prevention of bacterial infection
AU2003227257A1 (en)	2003-10-08	Medicine for prevention and/or therapy of cardiomyopathy
NO20054020D0 (no)	2005-08-30	Medisin for forhindring og behandling av arterosklerose og hypertensjon
IL151658A0 (en)	2003-04-10	Methods and compositions for the treatment or prevention of cardiovascular diseases
TW200514552A (en)	2005-05-01	A constituent for preventing of memory lose and dementia
HK1072713A (en)	2005-09-09	The treatment of pain with ifenprodil